"Neurotransmitter Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.
| Descriptor ID |
D018377
|
| MeSH Number(s) |
D27.505.519.625 D27.505.696.577
|
| Concept/Terms |
Neurotransmitters- Neurotransmitters
- Transmitter Substances, Nerve
- Substances, Nerve Transmitter
- Nerve Transmitter Substances
- Neurotransmitter
|
Below are MeSH descriptors whose meaning is more general than "Neurotransmitter Agents".
Below are MeSH descriptors whose meaning is more specific than "Neurotransmitter Agents".
This graph shows the total number of publications written about "Neurotransmitter Agents" by people in this website by year, and whether "Neurotransmitter Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 0 | 3 | 3 |
| 1997 | 1 | 2 | 3 |
| 1998 | 2 | 2 | 4 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 2 | 4 | 6 |
| 2003 | 2 | 2 | 4 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 4 | 5 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 3 | 6 | 9 |
| 2009 | 3 | 3 | 6 |
| 2010 | 2 | 3 | 5 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurotransmitter Agents" by people in Profiles.
-
Neurofeedback: new territories and neurocognitive mechanisms of endogenous neuromodulation. Philos Trans R Soc Lond B Biol Sci. 2024 Dec 02; 379(1915):20230081.
-
Medial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression. NMR Biomed. 2024 Nov; 37(11):e5220.
-
Monoallelic de novo AJAP1 loss-of-function variants disrupt trans-synaptic control of neurotransmitter release. Sci Adv. 2024 Jul 12; 10(28):eadk5462.
-
What's the n? On sample size vs. subject number for brain-behavior neurophysiology and neuromodulation. Neuron. 2024 Jul 03; 112(13):2086-2090.
-
GABAergic/Glycinergic and Glutamatergic Neurons Mediate Distinct Neurodevelopmental Phenotypes of STXBP1 Encephalopathy. J Neurosci. 2024 Apr 03; 44(14).
-
Co-transmitting interneurons in the mouse olfactory bulb regulate olfactory detection and discrimination. Cell Rep. 2023 12 26; 42(12):113471.
-
Spectrum of DDC variants causing aromatic l-amino acid decarboxylase (AADC) deficiency and pathogenicity interpretation using ACMG-AMP/ACGS recommendations. Mol Genet Metab. 2022 Dec; 137(4):359-381.
-
Advancements in the Quest to Map, Monitor, and Manipulate Neural Circuitry. Front Neural Circuits. 2022; 16:886302.
-
Advances in understanding cancer-associated neurogenesis and its implications on the neuroimmune axis in cancer. Pharmacol Ther. 2022 11; 239:108199.
-
Inhibition of calcium-triggered secretion by hydrocarbon-stapled peptides. Nature. 2022 03; 603(7903):949-956.